Literature DB >> 32829958

Pharmacology and safety of tofacitinib in ulcerative colitis.

Antonio López-Sanromán1, Juan V Esplugues2, Eugeni Domènech3.   

Abstract

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.
Copyright © 2020 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Colitis ulcerosa; Farmacología; JAK; Janus kinase; Pharmacology; Quinasas Janus; Safety; Seguridad; Tofacitinib; Ulcerative colitis

Year:  2020        PMID： 32829958     DOI： 10.1016/j.gastrohep.2020.04.012

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN： 0210-5705            Impact factor:   2.102


  7 in total

Review 1.  Therapeutic potential of pyrrole and pyrrolidine analogs: an update.

Authors:  N Jeelan Basha; S M Basavarajaiah; K Shyamsunder
Journal:  Mol Divers       Date:  2022-01-25       Impact factor: 3.364

2.  Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates.

Authors:  Vito Annese; Rahul Nathwani; Maryam Alkhatry; Ahmad Al-Rifai; Sameer Al Awadhi; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Mazen S Taha; Jimmy K Limdi
Journal:  Therap Adv Gastroenterol       Date:  2021-12-22       Impact factor: 4.409

3.  The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.

Authors:  Mikhail M Kostik; Rinat K Raupov; Evgeny N Suspitsin; Eugenia A Isupova; Ekaterina V Gaidar; Tatyana V Gabrusskaya; Maria A Kaneva; Ludmila S Snegireva; Tatyana S Likhacheva; Rimma S Miulkidzhan; Artem V Kosmin; Anastasia V Tumakova; Vera V Masalova; Margarita F Dubko; Olga V Kalashnikova; Ivona Aksentijevich; Vyacheslav G Chasnyk
Journal:  Front Pediatr       Date:  2022-02-08       Impact factor: 3.418

4.  Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome.

Authors:  Rajesh Panda; Pooja Singh; Saiteja Kodamanchili; Abhijeet Anand
Journal:  Indian J Anaesth       Date:  2021-10-28

Review 5.  User's guide to JAK inhibitors in inflammatory bowel disease.

Authors:  Ted A Spiewak; Anish Patel
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-03-03

Review 6.  MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer.

Authors:  Letizia Masi; Ivan Capobianco; Carlotta Magrì; Irene Marafini; Valentina Petito; Franco Scaldaferri
Journal:  Int J Mol Sci       Date:  2022-07-20       Impact factor: 6.208

Review 7.  Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction.

Authors:  Weixin He; Peixian Chen; Qingquan Chen; Zongtong Cai; Peidong Zhang
Journal:  Inflamm Res       Date:  2022-07-25       Impact factor: 6.986
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.